TRICAPITAL

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

FINDRA is a Scottish brand specializing in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish, versatile, and sustainable apparel made from Italian merino wool, which offers natural wicking properties. By providing high-quality clothing that balances performance and aesthetics, FINDRA encourages women to embrace outdoor activities and lead healthier, more active lifestyles. The brand's mission is to inspire women to pursue adventure without compromising on style or functionality, helping them to become better versions of themselves. Through its e-commerce platform, FINDRA promotes a commitment to sustainability while catering to the needs of adventurous women.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

My1Login Limited is a prominent provider of cloud-based password management and identity access solutions, headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Established in 2007, the company focuses on addressing enterprise cybersecurity threats through its next-generation Identity and Access Management (IAM) platform. My1Login's solution enables organizations to manage user identities effectively, providing a single user identity for employees and enhancing productivity while mitigating security risks. It supports various identity standards, including SAML, SCIM, OAuth 2.0, and OpenID Connect, and uniquely integrates with applications lacking standard connectors, such as legacy systems. The platform addresses issues like identity sprawl, password fatigue, and compliance adherence, facilitating secure onboarding and offboarding processes. My1Login's service is designed for rapid deployment, even in complex enterprise environments, ensuring comprehensive control over user identity and access while delivering a measurable return on investment.

Inquisitive Systems Ltd. is a data protection software company based in Edinburgh, United Kingdom, established in 2008 as a spin-out from Edinburgh Napier University. Founded by Dr. Jamie Graves and Professor Bill Buchanan, the company aims to become a leader in information security software. Inquisitive Systems developed its core technology, foxDNATM, during Dr. Graves' postgraduate research focused on enhancing digital forensic investigations. The software is designed to protect intellectual property from security breaches, analyze relevant data, provide alerts, and monitor forensic user activity. After securing a grant from Scottish Enterprise, the company began commercial operations in 2010, focusing on delivering innovative solutions to address growing cybersecurity challenges.

pureLiFi Ltd. is a light communications technology company based in Edinburgh, United Kingdom, that specializes in developing Li-Fi, a visible light communications technology. By utilizing the visible light spectrum instead of traditional radio frequencies, pureLiFi enables wireless data communication. The company offers various products, including Li-1st, which allows customers to develop and test VLC applications; Li-Flame, a secure wireless network solution; and the Li-Fire Platform, which supports wireless communications through light. Its technology is applicable in diverse fields such as smart lighting, healthcare, aviation, and location-based services, addressing issues like RF spectrum relief and enhancing mobile connectivity. Originally founded as pureVLC Ltd. in 2012, the company rebranded in 2013 to reflect its focus on Li-Fi solutions.

Blackford Analysis Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in enhancing the comparison of medical images to improve productivity in healthcare settings. Founded in 2010 as a spin-out from the University of Edinburgh, the company develops a range of tools designed for seamless integration into existing imaging systems. Key products include the Blackford Workflow Server, which facilitates the deployment of pre-processing capabilities within hospital IT frameworks, and the Blackford Smart Localizer, which allows for quick comparisons of multiple imaging studies with a single click. Blackford's software leverages advanced algorithms and multi-core processing technologies to deliver significant time savings—typically between 10% and 20%—for clinicians. The company collaborates with various imaging system providers, such as Philips and Intelerad Medical Systems, as well as industries beyond diagnostic imaging, to enhance diagnostic confidence and patient outcomes. Blackford Analysis continues to expand its presence, with sales offices in the United States and the United Kingdom.

Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.

IRT Surveys Limited, established in 2002 and headquartered in Dundee, UK, specializes in non-destructive building testing using infrared thermal imaging technology. The company offers a range of services including thermal imaging surveys, energy audits, air leakage detection, electronic leak detection, and maintenance planning. They also provide energy performance certificates to help clients identify defects and inefficiencies in their properties, enabling informed decision-making for future planning.

Actual Analytics is a provider of behavior analysis solutions for scientific studies, offering automated video-based tools to monitor laboratory animals. Its products include ActualTrack, which automatically tracks movement of animals such as rodents, drosophila, and zebrafish, and Actual Home Cage Analysis, a non-invasive data collection and automated behavior analysis tool for group-housed rodents. The company serves pharmaceutical and academic research markets, delivering continuous monitoring and detailed locomotor and behavioral outputs to accelerate disease research, improve reproducibility, and reduce manual effort in preclinical studies. It operates through distributors in the United States, Spain, Taiwan, China, and Germany and is headquartered in Edinburgh, United Kingdom. Actual Analytics was founded in 2009.

IRT Surveys Limited, established in 2002 and headquartered in Dundee, UK, specializes in non-destructive building testing using infrared thermal imaging technology. The company offers a range of services including thermal imaging surveys, energy audits, air leakage detection, electronic leak detection, and maintenance planning. They also provide energy performance certificates to help clients identify defects and inefficiencies in their properties, enabling informed decision-making for future planning.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company specializes in developing a patented Kromex chemistry scaffold aimed at generating New Chemical Entities (NCE) for regenerative medicine applications and mitochondrial-related diseases. The Kromex scaffold, informed by extensive research in free radical biology and redox chemistry, encompasses a library of over 100 million compounds with potential therapeutic effects on oxidative stress-associated diseases and mitochondrial dysfunction. Antoxis focuses on two primary drug families: Proxison, which enhances the efficacy of regenerative medicine therapies and holds promise for treating neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed to improve outcomes in drug-resistant cancer by demonstrating synergy with existing cancer treatments.

Biopta Ltd. is a contract research organization based in Glasgow, United Kingdom, specializing in human tissue-based services for the pharmaceutical industry. Founded in 2002, the company utilizes ethically donated residual human tissue from surgeries to predict drug activity prior to clinical trials. Biopta provides a range of services, including laboratory and comparative pharmacology, clinical biopsies, and both in-vitro and ex-vivo techniques. Their expertise spans several therapeutic areas, offering services related to cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary functions. In addition, Biopta maintains a catalogue of human functional tissue assays, which includes various standard assays. The organization operates laboratories in Glasgow and Maryland and functions as a subsidiary of ReproCELL, Inc. since December 2015.

Turnbull & Scott (Engineers) Ltd, established in 1933, is a British engineering company specializing in the generation, transfer, and recovery of heat. The company manufactures a range of products, including heat exchangers, heating and cooling coils, economizers, and waste heat recovery systems, designed to meet the heating requirements of various industrial and commercial applications. With over 80 years of combined experience across sectors such as nuclear, food processing, oil and gas, and pharmaceuticals, Turnbull & Scott has built a strong reputation for delivering robust and reliable heating solutions tailored for harsh environments or challenging locations. The company prides itself on its British manufacturing heritage and commitment to quality, supported by a highly skilled workforce. As an Investor in People and a partner of the University of Strathclyde, Turnbull & Scott is dedicated to advancing high-performance heating technologies to address contemporary industrial challenges.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company specializes in developing a patented Kromex chemistry scaffold aimed at generating New Chemical Entities (NCE) for regenerative medicine applications and mitochondrial-related diseases. The Kromex scaffold, informed by extensive research in free radical biology and redox chemistry, encompasses a library of over 100 million compounds with potential therapeutic effects on oxidative stress-associated diseases and mitochondrial dysfunction. Antoxis focuses on two primary drug families: Proxison, which enhances the efficacy of regenerative medicine therapies and holds promise for treating neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed to improve outcomes in drug-resistant cancer by demonstrating synergy with existing cancer treatments.

Gas Sensing Solutions Ltd. is a manufacturer of carbon dioxide sensors, headquartered in Glasgow, United Kingdom. The company specializes in innovative CO2 sensor technology that caters to various applications, including building control, horticulture, education, process control, and analytical instrumentation. Its product lineup includes the COZIR Ambient sensors, designed for HVAC and indoor air quality management; the COZIR Wide Range sensors, suitable for applications in diving, industrial safety, and automotive sectors; and the SprintIR, a high-speed CO2 sensor intended for metabolic assessment. In addition to its sensor products, Gas Sensing Solutions offers tailored hardware and software development services to meet specific client needs. Established in 2005, the company has positioned itself as a key player in the gas sensing industry.